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Introduction: Surgical site infection (SSI) is a common complication after vascular surgery. It may cause
exposure of the underlying prosthesis causing graft infection, which may require the removal of the
vascular graft, increasing amputation and mortality risks. Graft contamination usually occurs during
operative procedure or by direct spread from an infected wound. It is therefore advisable to a strong
effort in reducing SSI. Topic antibiotics have not been fully studied in vascular surgery, but collagen
implant with gentamicin sulphate has shown to reduce SSI in cardiac surgery, orthopaedics, and general
surgery procedures.Methods: Sixty (60) non-diabetic and non-obese patients with lower limb ischaemia
with indication for femoropopliteal PTFE prosthetic bypass were allocated into 2 groups of 30 patients. A
collagen implant impregnated with gentamicin sulphate (Collatamp®) was applied in the groin incision
adjacent to the prosthesis in one group, and the other was a control group. The same surgical team
operated all patients. Szilagyi classiﬁcation was used. Results: There was no SSI (0% e 0/30) in the
collagen implant with gentamicin sulphate group, contrasting with 6 cases (20% e 6/30) of SSI (grade I
and II) in the control group (p ¼ 0.024). In-hospital day's data shows a signiﬁcant difference between the
two groups (p ¼ 0.004) with a mean of 5.66 days for implant group and 8.10 days for control group. There
was no SSI grade III. Conclusion: Collagen implant with gentamicin sulphate (Collatamp®) reduces SSI in
the groin incision in ischaemic patients submitted to femoropopliteal PTFE prosthetic bypass. Days of
hospitalization are also reduced. Decreasing SSI rate and in-hospital days, this implant may also reduce
health care costs. Because this is a small pilot study, a multicentre RCT is necessary for validation.
© 2014 Surgical Associates Ltd. Published by Elsevier Ltd. All rights reserved.1. Introduction
Surgical site infection (SSI) is a common complication after
vascular surgery. Some prospective trials report an incidence of SSI
between 4% and 25%, but in retrospective studies there is an inci-
dence from 4% up to 43% [1,2]. In 184 consecutive patients from.E.P. Costa Almeida).
by Elsevier Ltd. All rights reservedseveral centres in Finland submitted to a range of vascular surgery
procedures the SSI rate was reported as 27% [2]. Turtiainen et al.
identiﬁed a higher rate of infection in patients who underwent
infrainguinal surgery [3]. SSI after vascular surgery may cause
exposure of the underlying prosthesis causing graft infection,
which is the most serious complication in vascular surgery occur-
ring from 1% up to 6% of all vascular procedures [2,4,5]. This
infection may require the removal of the vascular graft, increasing
amputation and mortality risks [1,2,4]..
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or by direct spread during early postoperative period [5,6]. Groin
incision is most likely at risk for SSI and prosthetic graft infection
because of surgical division of lymphatic channels, the proximity to
the perineum, the relatively superﬁcial localization of vascular
grafts in the groin, the development of wound infection adjacent to
the prosthesis [7,8], and the presence of skin folds. Infrainguinal
vascular surgery is a risk factor for infection [1,3], and a SSI rate of
2.5% has been reported. A mortality rate of 17% and an amputation
rate of 41% have been associated with infrainguinal arterial pros-
thesis infection [4]. SSI is also associated with an increase in health
costs [1,2], with a V3320 cost attributable to developing SSI in a
2010 study [3].
It is evident that SSI in an ischaemic patient submitted to fem-
oropopliteal PTFE prosthetic bypass can have catastrophic outcome
because of graft infection that can lead to limb amputation or even
patient death. It is therefore advisable to a strong focus on primary
prevention of infection, particularly for surgical procedures
involving prosthesis [9]. Systemic prophylactic antibiotics for24 h
was the only measure found to reduce SSI and prosthetic graft
infection in several trials [5,6,10]. Although topic antibiotics have
not been fully studied in vascular surgery, collagen implant with
gentamicin sulphate has shown to reduce SSI in cardiac surgery
[11,12], orthopaedics [13], and general surgery procedures [13e16].
Study the impact of collagen implant impregnated with genta-
micin sulphate e Collatamp® e on the SSI rate of groin incision in
ischaemic patients submitted to femoropopliteal PTFE prosthetic
bypass is the objective of this study.2. Methods
Sixty (N ¼ 60) non-diabetic and non-obese (BMI < 30) patients
with lower limb ischaemia (grade IIb, III and IV) with indication for
femoropopliteal bypass above or below knee were allocated in an
alternate method by the surgical team into 2 groups of 30 patients.
These eligible criteria were applied during ambulatory consultant
and in the emergency department. The study was enrolled in one
single centre with limited population. It began in 2006 and ended
in 2013, with a 30-day follow-up for each participant. A collagen
implant impregnated with gentamicin sulphate (Collatamp®) was
applied in the groin incision adjacent to the prosthesis in the
subfascial plane in one group (Fig. 1), and the other was a control
group who had no implant applied. In both groups a 24 h protocol
of systemic prophylactic antibiotic with 3 doses of piperacilin plus
tazobactan initiating 1 h before skin incision was administrated.
Skin was prepared with iodopovidone solution. Polytetraﬂuoro-
ethylene (PTFE) supported prosthesis were used, and all patients
were operated by the same surgical team. The SSI rate for the ﬁrst
30-day of follow-up was compared between the two groups. Szi-
lagyi classiﬁcation [17] was used, and the following broad criteriaFig. 1. The implant was applied in the groin incision (in the subfascial plane) adjacent to th
and facilitate its use.were used for SSI diagnosis: local excessive pain, local erythema
and oedema, pus drainage, suture dehiscence. The surgical team
was responsible for the follow-up.
Data collected for patients' characterization included: age,
gender, ischaemic grade, above or below knee bypass, right or left
lower limb. Because a higher ischaemic grade and a below knee
bypass can have both negative inﬂuence in SSI, participants were
allocated in an alternate method and these data were compared
between groups to conﬁrm their similarity. SSI rate and hospital
stay for both groups were analysed. A comparison of parameters
with vs. without Collatamp® was carried.
The statistical analysis was carried by means of SPSS for Win-
dows (version 20.0 SPSS Inc. USA). The continuous variables were
presented as means and medians, while standard deviations and
quartiles were chosen as measure of dispersion. Regarding their
normal distribution, the continuous variables were tested bymeans
of the ShapiroeWilk-test. While some of the tested variables did
not feature any normal distribution (p < 0.05), a normal distribu-
tion could be calculated for other variables (p  0.05). Thus, for the
comparison of the samples, tests for normally distributed samples
and non-parametric tests for non-normally distributed samples
were applied.
For the comparison of 2 independent, normally distributed
samples, the t-test was applied. Before that, the homogeneity of the
variances was tested by means of the Levene-test. Due to the
proven homogeneity of the variances, Student t-test was carried
out. For non-normally distributed samples the ManneWhitney-U-
Test was applied as a non-parametric procedure. The categorized
data, on the other hand, was evaluated bymeans of the exact Fisher
tests, whereby all necessary requirements for these tests were
fulﬁlled.
With all carried out tests, a two-sided signiﬁcance-test was
carried out. A p-value of <0.05 was assumed as statistically signif-
icance for all statistical tests.3. Results
During study period no participant was excluded. Surgery
length was about 90 mine120 min depending if it was above or
below knee bypass respectively. Data were compared between
implant and control groups concluding for the similarity of both.3.1. Age pattern
The mean of age for all 60 patients was 67.93 years old. The
groupwith the implant had amean of 68.53 y and the control group
67.33 y. There was no difference concerning age (p ¼ 0.635) be-
tween the two groups.e prosthesis covering the anastomosis. Saline solution was used to moister the implant
Table 1
Right or left and above or bellow knee bypass with vs. without Collatamp®. There is
no statistical difference (p > 0.05).
Data collected (% within
Collatamp)
Collatamp p
No Yes
Bypass Above knee 60% 53.3% 0.795
Below knee 40% 46.7%
Lower limb Right 40% 60% 0.196
Left 60% 40%
Graphic 2. SSI distribution. There was no SSI with collagen implant with gentamicin
sulphate, but 20% of patients without the implant had SSI. This is signiﬁcant
(p ¼ 0.024).
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In both groups 83.3% of the patients were males, and 16.7% were
females. After Chi-Square Test there was no difference between the
groups concerning the gender (p ¼ 1.000).
3.3. Ischaemic grade
Ischaemic grades IIb, III and IV were included in this one pro-
spective analysis. In the control group ischaemic grades IIb, III and
IV represented 66.7%, 23.3% and 10.0% of patients respectively. In
the implant group 80.0% of patients were grade IIb, 10.0% were
grade III, and 10.0% grade IV (Graphic 1). Comparing both groups it
was also evident that there was no difference between them con-
cerning ischaemic grade (p ¼ 0.375).
3.4. Above or below knee bypass
In the implant group 53.3% of patients were submitted to an
above knee bypass, and 46.7% to a below knee bypass. The distri-
bution in the control group was similar, with 60.0% of patients and
40.0% submitted to an above and below knee bypass respectively
(Table 1). Again, there was no statistical difference between them
(p ¼ 0.795).
3.5. Right or left lower limb
In the implant group 60.0% and 40.0% of patients were operated
to the right and left lower limb respectively. In the control group
40.0% of patients were operated to the right, and 60.0% to the left
lower limb (Table 1). There was one patient that was operated ﬁrst
to the right and two years later to the left lower limb. No difference
was found between the two groups (p ¼ 0.196).
After concluding for the similarity of both cases and control
groups surgical site infection and hospital stay were compared
between them. Szilagyi classiﬁcation was applied during follow-up
by the surgical team. There were no allergic reactions in all 30
patients with the implant.
3.6. Surgical site infection
In the implant group there was a SSI rate of 0% (0/30 patients)
comparing to 20.0% in the control group (6/30 patients) (Graphic 2).
This difference was statistically signiﬁcant (p ¼ 0.024). Of those 6
cases of SSI in the control group, 4 were grade I (13.3%), and 2 were
grade II (6.7%) according to Szilagyi classiﬁcation [17]. There wereGraphic 1. Ischaemic grade distribution in both groups (p ¼ 0.375).no grade III infections (Graphic 3). All SSI grades I and II were solved
with systemic antibiotic.
3.7. Hospital stay
Hospital stay was analysed in postoperative in-hospital days. If
no implant was applied there was a minimum of 4 and a maximum
of 20 postoperative days, mean of 8.10 days. However, if a collagen
implant with gentamicin sulphate was applied, a mean of 5.66
postoperative days (minimum of 3 and maximum of 11 days) was
found (Graphic 4). These results are statistically signiﬁcant
(p ¼ 0.004).
4. Discussion
SSI after vascular surgery may cause exposure of the underlying
prosthesis causing graft infection. In fact, bacteria dissemination
from an infected wound is the most frequent cause of vascular graft
infection [5]. With an amputation rate of 8%e52% and a mortality
rate of 13%e58% [7], vascular prosthetic graft infection is the most
serious complication in vascular surgery occurring from 1% up to 6%
of all vascular procedures [4,5]. Vascular infections and prosthesis
infections are both limb- and life-threatening [6].
Staphylococcus and gram-negative bacteria are the main cause
of SSI in vascular surgery [1,5,10,18], and because of that antibiotic
shall be active against these germs. Infectious diseases are
increasing because of bacteria resistance to antibiotics. Knowing
local standard of resistance is crucial for a correct prophylaxis and
treatment [6]. Systemic prophylactic antibiotic for24 h is the only
measure shown to reduce SSI, and there is no advantage to prolong
this [1,5,10] or to add anti-MRSA agents to prophylactic regimen
[6,18]. The use of piperacilin plus tazobactan for prophylaxis
probably was not the best choice since it is used in treatment.
However it is active against staphylococcus and gram-negatives,
Graphic 3. Slizagyi classiﬁcation of SSI.
Graphic 4. In-hospital days: with vs. without Collatamp®. Patients with the implant
had signiﬁcantly shorter hospital stay (5.66 days) than patients without the implant
(8.10 days). This difference is statistically signiﬁcant (p ¼ 0.004).
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spectrum antibiotic could have advantages. Topic antibiotics have
not been fully studied in vascular surgery, although collagen
implant with gentamicin sulphate has shown to decrease SSI in
cardiac surgery [11,12], orthopaedics [13] and several general sur-
gery procedures [13e16]. With topic application of collagen
implant with gentamicin sulphate (active against staphylococcus
and gram-negative germs) a local concentration high above mini-
mum inhibitory concentration (mic) is reached, and without toxic
effects since there is no systemic absorption [11,16,19e21]. Because
fall-off in local gentamicin concentration is rapid enough to prevent
long-term sub-inhibitory concentrations it reduces risk of antibi-
otic resistance, and there is no evidence of resistance with long-
term use [2,13,19e21]. Additionally, using collagen as a carrier has
effects on healing and haemostasis, and it is a well-tolerated
implant without side effects [2,13,14,20,21]. These are the reasons
that justify our choice as anti-infectious prophylactic drug. The
implant was applied in the groin adjacent to the prosthesis
covering the anastomosis to take advantage of the haemostatic
properties (Fig. 1).
Ischaemia grades IIb, III and IV were included. Grade IV could
have had a negative impact in the results, maybe prolonging in-
hospital stay and increasing infection risk. However both groups
were similar concerning ischaemic grade (p ¼ 0.375) with three
grade IV ischaemic patients in each group. In the Lee et al. paper thepresence of a non-healing wound in the extremity being re-
vascularized was not a signiﬁcant risk factor for SSI [22]. On the
other hand being grade IV patients the group with higher risk of SSI
and graft infection (comparing to IIb and III) after vascular surgery,
more patients will be needed in a multicentre randomized
controlled trial (RCT) so that solid conclusions could be made.
Having a small number of patients including grade IV patients is in
fact a weakness point of this pilot study. Concerning age, gender,
above or below knee bypass, right or left lower limb, there was no
statistical difference between both groups (p > 0.05).
There was no SSI (0%) in the implant group, contrasting with 6
cases (20%) of SSI in the control group. This difference was signif-
icant with p ¼ 0.024. SSI rate in the control group match other
studies data [1,2]. According do Szilagyi classiﬁcation there was 4
(13.3%) grade I infections (dermis), 2 (6.7%) grade II infections
(subcutaneous) and none (0%) grade III (arterial implant). By
decreasing SSI, collagen implant with gentamicin sulphate is ex-
pected to decrease graft infection, however a follow-up of one year
should be accomplished so that we can take any conclusion on
grade III infections. A multicentre RCT will need to evaluate graft
infection, which is the ultimate objective of using the implant.
Analysis of in-hospital day's data shows a signiﬁcant difference
between the two groups (p ¼ 0.004) with a mean of 5.66 days for
implant group and 8.10 days for control group. Maximum in-
hospital days for control group were 20 because of a grade IV
ischaemic patient, but there was no difference between groups
concerning ischaemia grade (p ¼ 0.375). Since this implant de-
creases SSI rate and in-hospital days, its use may reduce health care
cost in ischaemic patients submitted to femoropopliteal PTFE
prosthetic bypass.
A major disadvantage of this one-centre study is not being a
double-blinded one. We studied 30 patients in each group because
it is a one-centre study with limited population. For these reasons a
double-blinded multicentre RCT must be engaged for validation of
these results.
According to Gorbach guidelines the ideal anti-infectious agent
should prevent postoperative infectious morbidity and mortality,
should reduce the duration and cost of surgical care, should have no
adverse effects on the patient, and should have no adverse effects
on the microbial ﬂora of the patient or the hospital [13,23].5. Conclusion
Reduction of SSI rate in groin incisionmust be an objective for all
surgeons performing femoropopliteal PTFE prosthetic bypass.
Collagen implant with gentamicin sulphate reduces SSI in the groin
incision in ischaemic patients submitted to femoropopliteal PTFE
prosthetic bypass. Days of hospitalization are also reduced by the
topic use of collagen implant with gentamicin sulphate. Decreasing
SSI rate and in-hospital days, this implant may also reduce health
care costs.
However, because this is a small pilot study, a multicentre RCT is
necessary for validation of these results, and so that its use can be
routinely advised.Ethics
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